Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alligator Bioscience AB ( (SE:ATORX) ) has issued an update.
Alligator Bioscience AB has announced a rights issue of units worth approximately SEK 120 million, subject to approval at an extraordinary general meeting. The funds raised will be used to repay loans and support ongoing projects, including securing a partnership for mitazalimab. The rights issue is partially covered by subscription undertakings and guarantee commitments, and the company has also secured bridge loans to meet liquidity needs until the rights issue is completed.
More about Alligator Bioscience AB
Alligator Bioscience AB operates in the biotechnology industry, focusing on developing innovative antibody-based therapies for cancer treatment. The company is committed to advancing its pipeline projects and securing partnerships to enhance its market presence.
Average Trading Volume: 609,877
Technical Sentiment Signal: Sell
Current Market Cap: SEK143.7M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.